Helix BioPharma Corp. provides Polish subsidiary divestiture update

RICHMOND HILL, ON / ACCESSWIRE / August 31, 2020 – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immunooncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 …

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), is a clinical- stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center (“Moffitt”) for an additional year.